IONS Ionis Pharmaceuticals
- 40.650
- -0.470-1.14%
- 41.000
- +0.350+0.86%
Ionis Pharmaceuticals News
ALS Therapy Market Seen Increasing to Nearly $1.3B by 2029
Express News | Ionis Pharmaceuticals Inc : Bernstein Raises Target Price to $44 From $37
Express News | Ionis Pharmaceuticals Inc : Bernstein Raises to Market Perform From Underperform
Flamingo Therapeutics Announces Poster Presentation at EACR 2024 Congress on FLM-7523 (FTX-001), a First-in-Class Inhibitor of the Long Non-Coding RNA MALAT1
LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA , June 10, 2024 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced a poster presentation on FLM-7523 (also referred to as FTX-0
TD Cowen Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $54
TD Cowen analyst Yaron Werber maintains $Ionis Pharmaceuticals(IONS.US)$ with a buy rating, and maintains the target price at $54.According to TipRanks data, the analyst has a success rate of 54.0% an
Express News | Ionis Pharmaceuticals Inc : JP Morgan Cuts Target Price to $50 From $55
Unusual Options Activity: IONS, NCLH and Others Attract Market Bets, IONS V/OI Ratio Reaches 318.7
EST Jun 4th Afternoon Delivery - In the last two hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Express News | Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Ionis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/03/2024 59.7% Needham $60 → $60 Reiterates Buy → Buy 05/08/2024 118.26% Wells Fargo $85 → $82 Maintains
Flamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC)
-Trial-in-Progress poster provides overview on PEMDA-HN trial evaluating danvatirsen in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with recurrent/metastatic HNS
Most Shareholders Will Probably Agree With Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation
Key Insights Ionis Pharmaceuticals to hold its Annual General Meeting on 6th of June Salary of US$960.9k is part of CEO Brett Monia's total remuneration The total compensation is similar to the av
Ionis Pharmaceuticals' Donidalorsen: A Promising Drug Amidst Competitive Challenges and Market Uncertainties
Ionis Pharmaceuticals' Hold Rating Amid Promising HAE Trial Outcomes and Market Considerations
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
Friday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE).Donidalorsen had a favor
Ionis Pharmaceuticals' Donidalorsen Poised for Strong Market Penetration: A Buy Rating Endorsement
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen Inc's (NASDAQ:BIIB) Qalsody (tofersen) for amyotrophic
Ionis Hereditary Angioedema Therapy Succeeds in Late-stage Trials
Express News | Ionis Discloses Positive Results From OASIS-HAE And OASISplus Studies Of Investigational Medicine Donidalorsen In Patients With Hereditary Angioedema
Express News | Ionis Pharmaceuticals Inc: Plans to File a New Drug Application This Year With U.S. Food and Drug Administration
Express News | Ionis Pharmaceuticals Inc: Study Met Its Primary Endpoint
Analysis
Price Target
No Data
